Abstract
In April 1988, EuroCetus* submitted a marketing authorization application for Proleukin® to the CPMP using Italy as rapporteur. Thirteen months later, we received a positive opinion. Although the results of the concertation procedure were favorable, we did encounter some practical problems along the way. The views presented here are those of the author, not necessarily the company.
Get full access to this article
View all access options for this article.